This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary

BETHESDA, Md., Sept. 18, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the Company's German subsidiary, Northwest Biotherapeutics, Gmbh. 

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Dr. Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector.  He previously served as Head of Central Nervous System (CNS) therapeutics at Schering AG (now part of Bayer AG) with responsibility for research and development, and global marketing and sales, of CNS products.  This included such drugs as Dopergin (for Parkinson's disease) and Noctamide (a sleeping aid).

Dr. Rosskamp also served as Project Leader for the development and registration (product approval) of the blockbuster drug, Betaseron (for multiple sclerosis), in the European Union.

He subsequently served as Head of Strategic Business Development at Schering AG reporting directly to the Board and determining suitable opportunities in existing franchise areas of the Company, such as hormone products and diagnostics, and new franchise areas such CNS therapeutics and cardiology. 

Dr. Rosskamp also served as Vice President of Life Sciences and Chemicals at the German Industrial Investment Council (IIC).  In that role, he developed a broad network throughout the global pharmaceutical and life sciences industry, including in the US and Asia as well as in Europe.

Dr. Rosskamp served as CEO of three biotech companies, including a company developing treatments for inflammatory and immune disorders, and two companies developing cell therapy products.  Dr. Rosskamp's experience with clinical trials and regulatory requirements for such cellular products will be particularly useful for NW Bio.

"NW Bio's DCVax technology is one of the most exciting technologies I have seen in my career," commented Dr. Rosskamp, "and NW Bio has made impressive progress in their lead program for brain cancer in both the US and Europe, and in building a deep pipeline of additional applications and product lines.  I am very pleased to join NW Bio and help with the ongoing clinical development, and the registration and commercialization of their DCVax products."    

"We are excited to have Dr. Rosskamp, a widely respected industry veteran, join our Team," commented Linda Powers, CEO of NW Bio.  "Dr. Rosskamp's wealth of experience with physicians, regulators and industry throughout the German and European pharma and biotech sectors, will provide a strategic advantage in building NW Bio's operations in Europe." 

Dr. Rosskamp succeeds Dr. Bernhard Faber, who served as the interim start-up CEO of NW Bio's German subsidiary, and who also manages the Bioville, Gmbh consulting firm.  "We appreciate Dr. Faber's helpful role in the initial establishment and launch of our German subsidiary," said Linda Powers.  "Dr. Faber made an important contribution to our German program."

For further information about the Company and its programs, please visit the Company's website at www.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax ® dendritic cell-based vaccines.  The Company's lead program is a 300-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax ® for metastatic ovarian cancer. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax ® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,109.23 +57.50 0.34%
S&P 500 1,981.34 +7.71 0.39%
NASDAQ 4,449.5580 +24.8540 0.56%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs